Zions Bancorporation National Association UT Buys 5,094 Shares of Johnson & Johnson $JNJ

Zions Bancorporation National Association UT increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 59,630 shares of the company’s stock after acquiring an additional 5,094 shares during the quarter. Johnson & Johnson makes up about 0.5% of Zions Bancorporation National Association UT’s portfolio, making the stock its 25th largest position. Zions Bancorporation National Association UT’s holdings in Johnson & Johnson were worth $11,057,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in JNJ. Texas Yale Capital Corp. boosted its position in shares of Johnson & Johnson by 19.3% during the 3rd quarter. Texas Yale Capital Corp. now owns 35,057 shares of the company’s stock worth $6,500,000 after purchasing an additional 5,670 shares in the last quarter. Providence Financial Advisors LLC bought a new position in Johnson & Johnson in the third quarter worth approximately $1,134,000. MRA Advisory Group grew its stake in Johnson & Johnson by 13.5% in the third quarter. MRA Advisory Group now owns 2,948 shares of the company’s stock valued at $547,000 after acquiring an additional 351 shares during the period. Bell & Brown Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 14.2% during the third quarter. Bell & Brown Wealth Advisors LLC now owns 1,644 shares of the company’s stock valued at $305,000 after acquiring an additional 205 shares in the last quarter. Finally, Tobam raised its position in shares of Johnson & Johnson by 59.8% during the third quarter. Tobam now owns 19,780 shares of the company’s stock worth $3,668,000 after purchasing an additional 7,403 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer publicly praised J&J on-air, calling the company “amazing,” which can boost retail investor interest and provide short-term support for the stock. Johnson & Johnson (JNJ) Is Amazing, Says Jim Cramer
• Neutral Sentiment: Wall Street Zen cut JNJ to a Hold, signaling reduced upside conviction from at least one boutique research provider; that can temper buying enthusiasm but is not a major institutional downgrade. Johnson & Johnson (NYSE:JNJ) Cut to Hold at Wall Street Zen
• Negative Sentiment: A Pennsylvania jury found J&J liable in a talc/ovarian-cancer case and ordered $250,000 in damages to the family of Gayle Emerson — a reminder that ongoing talc litigation continues to create legal costs, uncertainty and headline risk for the company. Jury: Johnson & Johnson Liable in Case Linking Baby Powder to Cancer

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $243.37 on Monday. The company has a market capitalization of $586.51 billion, a PE ratio of 22.02, a PEG ratio of 2.36 and a beta of 0.35. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The stock’s 50 day moving average price is $217.25 and its 200-day moving average price is $196.79. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $246.35.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The business had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is presently 47.06%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on JNJ shares. HSBC upped their price objective on shares of Johnson & Johnson from $240.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. Guggenheim increased their price objective on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. Argus raised their target price on Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. Finally, UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $233.73.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.